Basic Company Data Data as of: March 17, 2011 Current Price $58.

25
Symbol JNJ JOHNSON & JOHNSON H&C Composite Score
Description Johnson & Johnson manufactures health care products and provides related
Strong Sell
services for the consumer, pharmaceutical, and medical devices and diagnostics
markets. The Company sells products such as skin and hair care products,
acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical
-3.2
equipment in countries located around the world.

Sector Health Care

Industry Pharmaceuticals, Biotechnology 0 1 2 3 4 5
Last Report Date 1/25/2011 Technical Score Fundamental Score
Earnings Date 4/19/2011 IPO Date #N/A N/A
Fundamentals Technicals
Market Cap. $159.3 B BETA 0.42 Price $58.25 MACD Trend Down
Price/Earnings 12.24 1Yr. EPS Growth Rate % 3.21% 50-Day MA $61.05 Stochastics OverSold
Forward Price/Earnings 11.35 5Yr. Avg. EPS Growth Rate % 8.15% 200-Day MA $60.98 RSI Signal Trend Down
Price/Book 2.82 EPS Growth QoQ 0.98% 50/200 Day MA $0.07 S/T Trend Down
Forward PEG Ratio 1.79 Revenue Growth QoQ -5.48% Volume Pressure 0.59 L/T Trend Down
Return on Equity 30.84 Dividend Yield 3.71% Average Daily Volume 10,913,736 Bull / Bear Bear Trend
LT Debt/Equity 16.18% Cash Flow Per Share 5.96 M-Score (0 - 100%) 15%
H&C Fundamental Score 1.4 H&C Technical Score -4.6
Ownership Data
Inst. Buy/Sell Ratio 1.24 Management Ownership 0.05% 50 Day Moving Average S/T Support L/T Support
% Change of Insider Holdings 0.68% Short Interest Ratio 1.90 20 Day Moving Average S/T Resistance L/T Resistance

JOHNSON & JOHNSON $65

$64

$63

$62

$61

$60

$59

$58

$57

5.0
Bull Trend Bear Trend

0.0

-5.0
1.5
Up / Down Volume Ratio
1.0
0.5
0.0
300

200

100

0
19-Nov-10 6-Dec-10 20-Dec-10 4-Jan-11 19-Jan-11 2-Feb-11 16-Feb-11 3-Mar-11 17-Mar-11
Volume x100,000
Fundamentals
JOHNSON & JOHNSON
1
Earnings Per Share 2
Reported Estimate Target Price 19 Reported Estimate
$1.40 $80

$1.20 $70

$60
$1.00
$50
$0.80
$40
$0.60
$30
$0.40
$20

$0.20 $10

$0.00 $0

Total Revenues 1
Reported Estimate
Ownership EPS & Revenue Growth
Investment Advisor 84.81% Quarter EPS Growth Rev. Growth
$18,000
Insurance Company 4.66% FQ1 2009 0% -7%
$16,000 Pension Fund (ERISA) 4.16% FQ2 2009 -3% -7%
Hedge Fund Manager 2.70% FQ3 2009 3% -5%
$14,000 Mutual Fund Manager 1.61% FQ4 2009 9% 9%
Bank 0.78% FQ1 2010 2% 4%
$12,000
Endowment 0.72% FQ2 2010 5% 1%
$10,000 Corporation 0.28% FQ3 2010 3% -1%
FQ4 2010 1% -5%
$8,000
Top Holders and % Outstanding Forward Growth Estimates
$6,000
STATE STREET CORP 5.05% Quarter EPS Growth Rev. Growth
$4,000 VANGUARD GROUP INC 3.77% FQ1 2011 -2% 1%
BLACKROCK INSTITUTIO 2.59% FQ2 2011 3% 4%
$2,000 BERKSHIRE HATHAWAY I 1.56% FQ3 2011 -1% 5%
BANK OF NEW YORK MEL 1.49% FQ4 2011 9% 4%
$0
STATE FARM MUTUAL AU 1.38%
NORTHERN TRUST CORPO 1.37%
ALLIANCEBERNSTEIN LP 1.25%

Largest Geographic Segmentation of Revenue Product Segmentation of Revenue

Yearly Yearly
Segment Name FY 2010 FY 2009 FY 2008 FY 2008 FY 2007 FY 2006 Segment Name FY 2010 FY 2009 FY 2008 FY 2008 FY 2007 FY 2006
United States 29,450.00 30,889.00 32,309.00 #N/A N/A 32,444.00 $29,775 Medical Devices and Diagnostics $24,601.00 $23,574.00 $23,126.00 #N/A N/A $21,736.00 20283
Europe 15,510.00 15,934.00 16,782.00 #N/A N/A 15,644.00 $12,786 Pharmaceutical $22,396.00 $22,520.00 $24,567.00 #N/A N/A $24,866.00 23267
Asia-Pacific, Africa 11,077.00 9,918.00 9,483.00 #N/A N/A 8,326.00 $7,221 Consumer $14,590.00 $15,803.00 $16,054.00 #N/A N/A $14,493.00 9774
Western Hemisphere excluding U.S. 5,550.00 5,156.00 5,173.00 #N/A N/A 4,681.00 $3,542

Disclosure: This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. This material is not a complete analysis of all material facts respecting any issuer, industry or
security or of your investment objectives, parameters, needs or financial situation, and therefore is not a sufficient basis alone on which to base an investment decision. Horowitz & Company clients may hold positions (long or short) in investments discussed. Please click for detailed
disclosures and additional information about our stock ratings and scoring.

3/17/2011